Puma Biotechnology Inc

PBYI · Moat type: REGULIERUNG

MoatScore

3/10

Fair Value

17 USD

Margin of Safety

+49.9 %

Rating

BEOBACHTEN

GESCHÄFTSMODELL Puma Biotechnology develops and commercializes targeted cancer therapeutics—primarily Neratinib, an orally administered irreversible pan-HER tyrosine kinase inhibitor—and generates revenues principally through product sales as well as licensing and milestone payments from partnerships.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.